Menu

Biocartis receives grant for development of a fully automated MSI test

Test could be validated as prognostic test for colorectal cancer and predictive test for cancer immunotherapies
Non-regulated information

Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

Study and editorial ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’ published in renowned clinical journal The Lancet Oncology
Non-regulated information

Important milestone in Biocartis-Merck collaboration with launch of second liquid biopsy assay

Non-regulated information

Biocartis submits 510(k) file with US FDA for Idylla™ platform

Submission done in parallel with 510(k) submission of Janssen Idylla™ Respiratory (IFV-RSV) Panel Test by Janssen Diagnostics
Non-regulated information

CE-marking Idylla™ NRAS-BRAF Mutation Test completes offering of metastatic colorectal cancer tests for clinical use on Idylla™ platform

Non-regulated information

Biocartis launches second liquid biopsy assay

Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma
Non-regulated information

Biocartis receives EUR 1.4m grant to support development of its rapid NGS Prep Panels

Non-regulated information

Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion

Minister Muyters, Flemish Minister of Work, Economy, Innovation and Sports visits Biocartis on 18 October 2016 to announce the grant
Non-regulated information

AstraZeneca Comparative Study confirms Best-In-Class Status of Idylla™ KRAS Mutation Detection Technology

Non-regulated information

Three Idylla™ Test Performance Studies to be presented at Esmo Oncology Conference

Non-regulated information